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1 INTRODUCTION 
 
1.1 Amyotrophic lateral sclerosis 
 
1.1.1 Clinical symptoms 
 
Amyotrophic lateral sclerosis (ALS; ORPHA803) is a fatal, neurodegenerative 
disorder characterized by the death of motor neurons in the brain, brainstem and 
spinal cord. The characteristic clinical course of ALS is a progressive loss of 
voluntary movement, with symptoms spreading to more distant locations, resulting in 
paralysis and death from respiratory failure (Morrison and Harding, 1994). 
Amyotrophic refers to the lack (a-) of muscle (-myo-) nourishment (-trophic), 
resulting in wasting of the fibers; Lateral refers to the lateral corticospinal tract of 
affected neurons between the brain and spinal cord; Sclerosis is the resultant 
hardening of the tissue. ALS is also termed Charcot’s disease after Jean Martin 
Charcot (French clinician) who first described its features in 1869 (Charcot, 1869) or 
Lou Gehrig’s disease in the United States, after the famous New York Yankees 
baseball player afflicted with the condition. 
 
Originally, the spectrum of adult motor neuron diseases (MND) included ALS with 
the combined degeneration of upper (cortical) and lower (pontobulbar and spinal) 
motor neurons, primary lateral sclerosis (PLS) with only upper motor neuron lesion 
and lower MND with the damage of pontobulbar and/or spinal motor neurons (Victor 
and Ropper, 2000). In a recent work, Finsterer and Burgunder (2014) suggested that 
ALS can manifest clinically as a continuum ranging from exclusive impairment of 
the upper motor neurons to exclusive impairment of the lower motor neurons. These 
observations have resulted in the now commonly held belief that ALS is a syndrome 
rather than a specific disease. As a result of the heterogeneity of presentation the 
exclusion of ALS mimics is an extremely important part of diagnosis (Chio et al. 
2011; Chang RCC, 2011). 
Exclusive impairment of the upper motor neurons can manifest in PLS characterized 
by spastic paresis of the striated muscles without atrophy and denervation, increased 
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deep tendon reflexes, pathological reflexes designating upper motor neuron lesion 
(Finsterer and Burgunder, 2014). Exclusive impairment of the lower motor neurons 
can contribute to the development of lower MNDs observed as atrophy of the striated 
muscles of the body due to degeneration of lower motor neurons with increasing 
weakness, decreased muscle tone, electrophysiological signs of denervation 
(fasciculations, fibrillations), lack of the deep tendon reflexes and, finally, inevitable 
death from respiratory failure (Finsterer and Burgunder, 2014; Victor and Ropper, 
2000). The onset is usually asymmetrical, and a smaller group of patients have 
“bulbar onset” ALS, which targets muscles of the face and neck. This form has a 
worse prognosis and it is more common in women (Forbes, et al., 2004; McCombe 
and Henderson, 2010).  
 
Familial forms account for about 10% of ALS cases, although higher levels have 
been reported in certain geographical regions (Murros and Fogelholm, 1983). The 
mean age of onset (at approximately 48-52 years) for familial ALS (FALS) is earlier 
than the mean age (at about 56 years) for sporadic ALS (SALS) and the survival 
period is also shorter for FALS than for SALS (Mulder et al. 1986; Li et al., 1988; 
Strong et al., 1991; Hewitt et al., 2010). A small minority of ALS patients show 
juvenile onset (typically before age 25), which is usually characterized by longer 
survival (Aggarwal and Shashiraj, 2006). The male to female ratio is 1.6 to 1. The 
lifetime risk for developing the disease is approximately 1/400 (Johnston et al., 
2006). ALS has a very poor prognosis, with a median survival period of three years 
after the onset of the initial symptoms (Hardiman et al., 2011). There is no cure for 
this relentless disease, although the drug riluzole, which blocks the release of 
glutamate, has been shown to slow disease progression (Bensimon et al., 1994). 
Despite numerous attempts at identifying other drugs, no further agents have risen to 
the level of significance.  
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1.1.2 Genetic background 
 
The genetics of ALS are of research interest because it helps to uncover the 
mechanism of cell death in ALS. Neuronal cytoplasmic protein aggregation and 
defective RNA metabolism show to be frequent pathogenic mechanisms involved in 
ALS. Regarding its genetic background, more than 20 major ALS genes (Table 1) 
have been implicated in the Mendelian ALS forms and further about 100 genes have 
been associated as predisposing factors with the non-Mendelian variants (ALSoD 
Database, http://alsod.iop.kcl.ac.uk). ALS can be inherited in an autosomal dominant, 
autosomal recessive or X-linked manner. Familial forms are mainly transmitted in a 
Mendelian pattern of autosomal dominant inheritance (Hardiman et al., 2011). 
Several twin studies have estimated the genetic contribution to the risk for ALS to be 
quite high (61%), but the genetic background remains poorly understood (Al-Chalabi 
et al., 2010). Non-genetic risk factors, including environmental factors and physical 
injury, are being actively investigated. Although the contribution of these risks is 
difficult to expain (e.g. the prevalence of ALS in athletes), the involvement of these 
factors may enhance underlying, genetic predispositions to the disease. 
 
 
 
  
Figure 1. Gene frequencies in ALS - each gene is plotted against the year it was 
found; the size of the circles signifies the frequency of mutations in FALS or ALS as 
cited in the literature (Alsultan, et al., 2016) 
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Genetic subtype Gene Inheritance Chromosome 
ALS1 SOD1 AD, AR 21q22.11 
ALS2 Alsin AR 2q33.2 
ALS3 Unknown AD 18q21 
ALS4 SETX AD 9q34.13 
ALS5 SPG11 AR 15q14 
ALS6 FUS AD, AR 16p11.2 
ALS7 Unknown AD 20p13 
ALS8 VAPB AD 20q13.33 
ALS9 ANG AD 14q11.1 
ALS10 TARDBP AD,AR 1p36.22 
ALS11 FIG4 AD 6q21 
ALS12 OPTN AD, AR 10p13 
ALS13 ATXN2 AD 12q23-q24.1 
ALS14 VCP AD 9p13 
ALS15 UBQLN2 SD Xp11.21 
ALS16 SIGMAR1 AD 9p13 
ALS17 CHMP2B AD 3p12.1 
ALS18 PFN1 AD 17p13.3 
ALS19 ERBB4 AD 2q33.3-q34 
ALS20 HNRNPA1 AD 12q13.1 
ALS21 MATR3 AD 5q31.2 
ALS-FTD1 C9orf72 AD 22q11.23 
ALS-FTD2 CHCHD10 AD 9p21.2 
ALS TBK1 AD 12q14.2 
Table 1. The major ALS genes that 
are implicated in the Mendelian 
forms of ALS. (ALSoD Database). 
The genes investigated in this study 
are  shaded. 
10 
 
1.1.2.1 Superoxide dismutase 1 (SOD1) 
 
Among the ALS causative genes, superoxide dismutase 1 (SOD1) is one of the most 
commonly mutated genes and accounts for approximately 12–23% of the familial 
and up to 7% of the sporadic ALS forms (Andersen, 2006). SOD1 gene encodes the 
Cu/Zn superoxide dismutase enzyme, which catalyzes the inactivation of superoxide 
into oxygen and hydrogen peroxide, providing antioxidant defense (Smirnoff, 1993).  
The SOD1 enzyme is widely expressed and constitutes approximately 0.5–0.8% of 
the soluble proteins in the brain (Pardo et al., 1995). Proper coordination of the Cu++ 
and Zn++ ions provides conformational steadiness to the dimeric SOD1 protein as 
well as extreme resistance against denaturing conditions (Arnesano et al., 2004). To 
date, more than 170 mutations have been reported for SOD1 in the Amyotrophic 
Lateral Sclerosis Online Genetics Database (ALSoD Database; Abel et al., 2012) 
since the gene was firstly associated to ALS in 1993 (Rosen et al., 1993). SOD1 
mutations occur in all the five exons of the gene.  
 
1.1.2.2 TAR DNA binding protein (TARDBP) 
 
Human TDP-43 was discovered in a screen for transcriptional repressors of the 
transactive response (TAR) DNA binding element of the HIV-1 virus in 1995 (Ou et 
al., 1995). TDP-43 is a 414-amino acid nuclear protein encoded by the TARDBP 
gene on chromosome 1p36.22 and, because of its molecular weight of 43kDa it was 
named TDP-43 (Buratti and Baralle, 2008). Since the TDP-43 association in ALS 
was initially described in 2006 (Neumann et al., 2006) more than 40 mutations have 
been found in familial and sporadic ALS cases (ALSoD Database; Lattante et al., 
2013). The TARDBP gene contains 6 exons, and with one exception (p.D169G in 
exon 4), all the identified mutations are located in the last exon (Kabashi et al., 2008; 
ALSoD Database). TDP-43 is mainly expressed in the nucleus and contains two 
RNA recognition motifs (RRM1 and RRM2) and a glycine-rich C-terminal region 
(GRR). TDP-43 is a DNA/RNA binding protein, and its functions include 
involvement in gene transcription, RNA splicing, microRNA processing and 
transport of mRNA (Chen et al., 2013). TARDBP gene is highly conserved from 
human to C. elegans. According to in situ hibridization studies described by 
Shakaran et al. (2008), TDP-43 is expressed early in the spinal cord and brain of 
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zebrafish. Ubiquinated inclusions were found in the motor neurons of ALS patients 
and TDP-43 was the major component of these inclusions (Neumann et al., 2006).   
 
1.1.2.3 Angiogenin (ANG) 
 
The ANG gene encodes angiogenin, a 123-residue, 14.1-kDa protein and it is located 
on chromosome 14q11.2. The ANG protein belongs to pancreatic ribonuclease 
superfamily, and it plays a role in rRNA biogenesis, cellular proliferation and has a 
crucial role in inhibiting protein translation by cleaving tRNA. It is known that ANG 
mediates neovascularization and promotes neurite outgrowth during early embryonic 
development and it protects against hypoxia-induced motor neuron death (Sebastia et 
al., 2009; Chen et al., 2013). 
Greenway et al. (2004) identified ANG as a candidate gene for amyotrophic lateral 
sclerosis in Irish and Scottish populations. ALS caused by mutations in the ANG 
gene is named as ALS9, an autosomal dominant adult onset disease. To date, 29 
variants have been described for ANG in the ALSoD database. Mutations in ANG 
gene cause loss of ribonucleolytic activity and nuclear translocation activity (Chen et 
al., 2013). The ANG (123-residue protein) is synthesized with a signal peptide of 24 
amino acids that is cleaved to form the mature protein. The mature protein contains a 
receptor binding region, an RNase A canonical domain, a nuclear localization signal 
sequence, and a catalytic site responsible for a low ribonuclease activity (Sheng and 
Xu, 2016).  
 
1.1.2.4 Chromosome 9 open reading frame 72 (C9ORF72) 
 
A frequently mutated ALS gene is chromosome 9 open reading frame 72 (C9orf72), 
which – in addition to the SOD1 mutations – is now recognized as the main cause of 
familial and sporadic ALS (Majounie et al., 2012; Gijselinck et al., 2012; Ratti et al., 
2012;  Smith et al., 2013). A hexanucleotide (GGGGCC) repeat expansion (RE) 
located in the non coding region of the gene that can reach up to 4400 units (normal 
range: 2-23 units) has been identified in patients with ALS and/or frontotemporal 
dementia. The GGGGCC RE contributes to 23–47% of familial ALS and to 4–5% of 
sporadic cases (Renton et al., 2011; DeJesus-Hernandez et al., 2011; Byrne et al., 
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2012; Ratti et al., 2012), with a frequency depending on geographical origin. 
Although the pathomechanism with which the hexanucleotide RE leads to the 
development of ALS has not been elucidated completely, both C9orf72 
haploinsufficiency gain of function mechanisms (driven by toxicity of sense and 
antisense RNA transcripts and derived dipeptide repeat proteins) have been reported 
(Taylor et al., 2016). Apart from the repeat expansion a splice site mutation has been 
identified in the C9orf72 gene (Liu et al., 2016).  
 
1.1.2.5 Senataxin (SETX) 
 
Mutations in the senataxin (SETX) gene have been identified at a lower frequency 
than in the SOD1 gene in ALS. SETX encodes a helicase protein involved in DNA 
repair and RNA production. Homozygous or compound heterozygous SETX 
mutations are associated with the development of autosomal recessive ataxia with 
oculomotor apraxia type 2 (AOA2) (Anheim et al., 2009). In addition, 
heterozygous SETX mutations have been associated with the autosomal dominant 
form of juvenile-onset ALS (ALS4) (Chen et al., 2004).  
 
1.1.2.6 Fused in sarcoma (FUS) 
 
The fused in sarcoma (FUS) gene is also associated with the Mendelian forms of 
ALS. FUS is located on chromosome 16p11.2 and encodes for a 526 amino acid 
protein. FUS is a nucleoprotein that plays a role in transcription, splicing, and 
shuttling of RNA from the nucleus to the cytoplasm. Fused in sarcoma also acts as a 
transcriptional regulatory sensor of DNA damage signals and therefore is required in 
maintaining the integrity of the genome (Zinszner et al., 1997). To date, 80 mutations 
of the FUS gene have been described (ALSoD Database) since the gene was firstly 
associated to ALS in 2009 (Vance et al., 2009; Kwiatkowski et al., 2009). 
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1.2 Aims 
 
In my thesis, the primary aim was to summarize the results of my genetic 
investigations in a group of Hungarian patients (n=66) suffering from ALS. I 
investigated the contributions of six commonly mutated ALS genes, SOD1, 
TARDBP, ANG, FUS, SETX and C9orf72. Besides, the genetic investigations aiming 
to identify the disease-causing mutations, it was also among my goal to compare 
these variants with the reported ones in the literature in order to define genotype-
phenotype correlations and Hungarian population specific mutations. 
This study represents the first genetic screening of ALS in Hungary, which adds 
novel data to the genetic and phenotypic diversity of this disease.   
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2 PATIENTS AND METHODS 
2.1 Patients 
 
The unrelated patients (n=66) included in this study were recruited from the 
Department of Neurology, University of Szeged, Szeged, Hungary, between 2010 
and 2016. The group consisted of 45 females and 21 males and the median of the age 
at onset was 60. All patients fulfilled the revised El Escorial and the Awaji-shima 
criteria for ALS (de Carvalho et al., 2009; Ludolph et al., 2015). According to the 
revised El Escorial criteria, the lower motor neuron disease (progressive muscular 
atrophy: PMA) is determined as one of the ”restricted phenotypes” of ALS, therefore 
one patient with only lower motor neuron involvement was also diagnosed as 
ALS. All patients and age- and sex-matched healthy controls (n=110) were of 
Hungarian ancestry. The investigation was approved by the Internal Ethical Review 
Board of the University of Szeged. Written informed consent was obtained from 
patients and healthy controls, and the study was conducted according to the 
Principles of the Declaration of Helsinki. 
 
2.2 Methods 
2.2.1 DNA isolation 
 
Blood samples from all the enrolled individuals (n=66) were collected after the 
individuals had signed an informed consent document. Genomic DNA was isolated 
using a QIAamp DNA Blood Mini Kit (QIAGEN; Hilden, Germany). 
2.2.2 Mutation Screening – Sanger Sequencing 
 
The entire coding region and the flanking introns of the SOD1, TARDBP and ANG 
genes were amplified (primer sequences used were taken from the UCSC Genome 
Browser www.genome.ucsc.edu). PCR was performed using Dream Taq Green PCR 
Master Mix (Fermentas) according to the manufacturer’s instructions. Direct 
sequencing of the PCR products was performed on an ABI 3100 sequencer and 
compared with the wild-type gene sequences at the Ensemble Genome Browser 
(http://ensemble.org). To identify known variations, I used ALS Online Genetics 
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Database (http://alsod.iop.kcl.ac.uk/) (Abel et al., 2012), 1000 Genomes Database 
(www.1000genomes.org/), dbSNP (http://www.ncbi.nlm.nih.gov/project/SNP) and 
Exome Aggregation Consortium (ExAC) database (http://exac.broadinstitute.org). To 
predict the functional effects of novel mutations, the sequence variations were 
assessed by in silico prediction programs, such as SIFT (http://sift.bii.a-star.edu.sg/), 
Polyphen-2 (http://genetics.bwh.harvard.edu/pph2) and Mutation Taster 
(http://mutationtaster.org). To examine possible effects of the mutations on the three-
dimensional (3-D) structure of the SOD1 protein, I used the Swiss-Model protein 
structure homology-modeling server (http://swissmodel.expasy.org/; SOD1 Protein 
Data Bank accession number 4b3e.1.A).   
Fragments with identified mutations were independently re-amplified and 
resequenced from both ends. 
 
2.2.3 Repeat expansion analysis 
2.2.3.1 Repeat-primed PCR and Fragment length analysis 
 
A two-step protocol proposed by Akimoto et al. (2014) was followed for the 
detection of the GGGGCC hexanucleotide RE in the C9orf72 gene. Fragment length 
analysis was performed using GeneMapper ID v3.2.1, and the samples producing a 
single peak product were further analyzed in the second step by repeat-primed PCR 
using 310 ABI Prism Genetic Analyzer (Applied Biosystems). The peaks were 
visualized using GeneMapper ID v3.2.1 software (Akimoto et al., 2014). The 
presence of the GGGGCC RE was observed as a saw-tooth pattern with 6-base pair 
periodicity.  
2.2.3.2 Genotyping 
 
To determine whether the single individual carrying the GGGGCC RE identified in 
this study also carried the “risk” haplotype, I selected the rs3849942 variant to be 
used as a marker for the “risk” haplotype for the patient and control genotypes. 
Rs3849942 genotyping was based on allelic discrimination assays using TaqMan 
chemistry following the manufacturer’s instructions (Life Technologies; Budapest, 
Hungary). 
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2.2.4  Targeted High-troughput sequencing 
2.2.4.1 Library preparation and sequencing 
 
Amplicons (n=56) were designed (range 519–704 bp; mean: 612 bp) to cover the 
coding regions and the flanking introns of the investigated FUS, 
SETX and C9orf72 genes, and amplicon libraries were prepared according to 
the Amplicon Library Preparation Manual for the Roche Junior 454 next generation 
sequencing system (Roche; Budaörs, Hungary). Template-specific primers were used 
in the first round PCR, which represented the target-specific step of the library 
preparation. The target specific primers provided ’universal tails’. Then a second 
round of PCR was carried out, targeting the ’universal tails’ and adding the MID-
labeled Primer A and Primer B sequences to barcode the samples. For each DNA 
sample, separated amplicon PCR amplifications were performed using FastStart High 
Fidelity PCR System (Roche; Budaörs, Hungary) with 50ng genomic DNA per 
reaction. PCR products were visualized on a 2.0% agarose gel by 
electrophoresis.Amplicons were purified with the Agencourt AMPure XP kit 
(Beckman Coulter; Budapest, Hungary), quantified with the Quant-iT PicoGreen 
Assay (Life Technologies; Budapest, Hungary), diluted separately to 
1x107 molecules/µl and pooled. Emulsion PCR and next generation sequencing were 
performed according to the manufacturers’ protocols (Roche). 
2.2.4.2 Bioinformatic analysis 
 
To improve the efficiency of the Roche pipeline, composed of the Roche 454 GS 
Reference Mapper for mapping (on UCSC human reference genome hg19) and 
Amplicon Variant Analyzer (v2.5p1) for variant calling, an additional in house 
pipeline was used. Sequencing reads were aligned to the reference genome (UCSC 
hg19) using Roche 454 GS Reference Mapper and Amplicon Variant Analyzer 
(version 2.5p1). BAM files were converted to FASTQ and realigned to hg19 using 
Bowtie2 V.2.2.6 (Langmead et al., 2012). Samtools V.0.1.19 and Python V.2.7.11 
were used for additional file handling. Variant calling was performed combining 
GATK Unified Genotyper (Genome Analysis Tool Kit v.3.4) (McKenna et al., 2010) 
and Platypus (v.0.8.1) (Rimmer et al., 2014). The annotation and the prioritization 
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steps were executed with ANNOVAR (15.06.07) (Wang et al., 2010). Finally, the 
target region reads depth was controlled using BEDTools (v.2.25.0) (Quinlan et al., 
2010) and the alternative allele frequency was computed using pysamstats (v.0.24.2) 
(https://github.com/). Candidate variants were filtered according to read depth, allele 
frequency and prevalence in genomic variant databases such as ExAc (v.0.3), 
ClinVar, Kaviar (including 1000g-phase3, dbSNP146) (Glusman et al., 2011; 
Landrum et al., 2016). Variant prioritization tools (PolyPhen2, SIFT, LRT, 
MutationTaster, Mutation Assessor) were used to predict the functional impact and 
then focused on variants with predicted deleterious consequences (nonsense SNVs, 
frameshift indels, essential splice variants and complex indels). The putative effect 
on splicing efficiency was predicted using the Human Splicing Finder (Desmet et al., 
2009). The alignments were visualized with IGV V.2.0.34 (Robinson et al., 2011). 
All the identified disease-causing candidate variants were confirmed by direct 
sequencing. 
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3 RESULTS 
 
3.1 SOD1 gene 
 
The direct DNA sequencing approach identified four different mutations of the SOD1 
gene in 5 ALS patients: three known heterozygous missense mutations (c.43G>A 
p.Val14Met; c.272A>C p.Asp90Ala; c.435G>C p.Leu144Phe) and one novel 
mutation (c.275_276delAA, p.Lys91ArgfsTer8) (Table 2.).  
3.1.1 Novel mutation detected in the SOD1 gene 
 
The detected novel heterozygous mutation (c.275_276delAA, p.Lys91ArgfsTer8) is 
located in the fourth exon of the SOD1 gene (Figure 2) and led to a frameshift with 
the insertion of 8 novel amino acids and the formation of premature stop codon at the 
new amino acid position 99. Analysis using Mutation Taster software predicted that 
the p.Lys91ArgfsTer8 mutation causes severe truncation of the encoded enzyme, 
and, thus, I hypothesize that this mutation is likely to be pathogenic (Figure 3). The 
pathogenic role of the p.Lys91ArgfsTer8 mutation is further supported by the fact 
that it interferes with the integrity of the Cys57-Cys146 disulfide bond, and results in 
the weakening of the dimer interface. 
 
 
Figure 2. A novel p.Lys91ArgfsTer8 mutation in the Cu-Zn superoxide dismutase 1 
(SOD1) gene identified by direct sequencing (Tripolszki et al., 2017a) 
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The novel p.Lys91ArgfsTer8 SOD1 mutation was not present in 110 healthy controls 
of Hungarian ancestry that I investigated, neither it is represented in mutation 
databases, including Single Nucleotide Polymorphism Database 
(http://www.ncbi.nlm.nih.gov/projects/SNP/), 1000 Genomes 
(www.1000genomes.org/), Exome Aggregation Consortium (ExAC) database 
(http://exac.broadinstitute.org) and the ALS Online Genetics Database 
(http://alsod.iop.kcl.ac.uk/) (Abel et al., 2012). Unfortunately, the segregation of this 
mutation could not be investigated because DNA samples from other family 
members were not available. 
 
3.1.1.1 Clinical features of the patient with the p.Lys91ArgfsTer8 SOD1 mutation 
 
This novel mutation was carried by a female Hungarian patient suffering from 
sporadic ALS, who reported a story of breast cancer eight years before the onset of 
ALS disease. The breast cancer, located on the left side, was surgically removed and 
irradiation therapy and anti-estrogen medication was introduced after the operation. 
On subsequent follow up investigation, the patient was tumor-free. However, eight 
years after the breast cancer, her lower extremities became clumsy and weak because 
of spasticity and muscle atrophy as a result of right peroneal palsy. On examination, 
the patellar reflexes were hyperactive while the Achilles reflexes were diminished. 
The weakness showed distal predominance. The muscle strength of the upper 
extremities were preserved, but the deep tendon reflexes were exaggerated. She also 
had dysphagia with increased gag reflex, dysarthria and bilateral recurrent nerve 
Figure 3.The crystallographic model shows that the novel frameshift mutation causes a 
severe truncation of the protein (Tripolszki et al., 2017a) 
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palsy with coarse voice. The calculated ALS Functional Rating Scale R (ALSFRS-R 
score; Cedarbaum et al., 1999) was 39/48 at the first examination, which was four 
months after the appearance of the first symptoms. Fasciculations of the striated 
muscles in all the extremities were seen. Electromyography (EMG) showed signs of 
denervation (fasciculations, fibrillations, positive sharp waves), a complete 
interference pattern did not develop in full effort and several enlarged motor units 
were recorded. Electroneurography (ENG) exhibited motor axonal loss. Serum level 
of creatine kinase was 238 U/l (normal < 170). The serum levels of thyroid hormones 
and parathyroid hormone were normal; however, the anti-thyroglobulin IgG level 
was almost five times higher than the normal value: 543.5 iu/ml (normal < 115). 
There were no alterations in the immunoglobulin levels of the serum, and 
monoclonal gammopathy or elevated anti-ganglioside IgG or IgM were not detected. 
Magnetic resonance imaging (MRI) demonstrated spondylosis and multiple 
protrusions of the intervertebral discs in the cervical and lumbar regions of the spinal 
cord without stenosis of the spinal canal, myelopathy and root lesions. MRI of the 
scull revealed only a few lacunar infarcts in the white matter of the cerebrum. The 
patient had been treated for hypertension and hypercholesterolemia for several years. 
She was given 2x50 mg riluzole/day; subsequently her status deteriorated quickly, 
and she became tetraplegic with dysarthria and dysphagia. Respiratory failure 
developed because of the weak respiratory muscles and she died at home.  
 
3.1.2 Detected known mutations of the SOD1 gene  
 
The SOD1 p.Leu144Phe mutation is located in the fifth exon of the gene and was 
identified in two female ALS patients (Figure 4). One of the patients reported that her 
maternal grandfather had suffered from non-progressive paralysis and weakness for 
20 years. The other patient reported that her paternal grandmother had suffered from 
a disease similar to her own. In this study, only the latter patient was therefore 
considered as having a familial form of the disease.  
The p.Val14Met mutation is located in the first exon of the SOD1 gene and was 
present in an affected female patient who reported no family history of ALS (Figure 
5). ALS symptoms first appeared at the age of 62. This patient showed lower and 
upper motor neuron signs. The disease course was progressive and led to the 
patient’s death within one year after disease onset. 
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Figure 5. The wild type DNA sequence and the DNA sequence of the 
affected patient  that shows the p.Val14Met  mutation.  
Figure 4. The wild type DNA sequence and the DNA sequence of the 
affected patient  that shows the p.Leu144Phe  mutation.  
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The p.Asp90Ala mutation, which is the most prevalent SOD1 mutation in Europe 
(Andersen et al., 1995; Al-Chalabi et al., 1998; Andersen, 2001), is located in the 
fourth exon of the SOD1 gene and was present in a female patient (Figure 6). 
Interestingly, the patient also carried the rs111273304 splice-donor variant 
(c.239+2T>A), which is of unknown significance, in heterozygous form. This patient 
had clinical features typically associated with this genotype, including a relatively 
long survival after onset (Andersen, 2006).  
 
 
 
 
  
Figure 6. The wild type DNA sequence and the DNA sequence of the 
affected patient  that shows the p.Asp90Ala  mutation.  
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3.2 TARDBP gene 
 
Direct sequencing of the TARDBP gene revealed a previously described missense 
mutation in exon 6 (c.931A>G, p.Met311Val) (Figure 7). The variant was first 
described by Lemmens et al. (2009) in a family of Belgian origin. The Hungarian 
patient with the p.Met311Val variant reported no family history and the ALS 
symptoms first appeared at the age of 62.  
 
 
 
 
 
3.3 ANG gene 
 
Mutation analysis of the angiogenin gene revealed two heterozygous mutations 
(c.3G>A, p.Met-24Ile#, p.Met1Ile*; c.169C>T, p.Arg33Trp#, p.Arg57Trp*).  
The p.Met-24Ile mutation is located in the signal peptide region of the protein, and it 
was initially described by Conforti et al. (2008) in a sporadic patient from Italy. This 
mutation (Figure 8) was detected in the same Hungarian patient who carried the 
SOD1 p.Val14Met mutation.  
Figure 7. The wild type DNA sequence and the DNA sequence of the affected 
patient  that shows the p.Met311Val  mutation. 
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Figure 8. The wild type DNA sequence and the DNA sequence 
of the affected patient  that shows the p.Met-24Ile  mutation.  
Figure 9. The wild type DNA sequence and the DNA sequence of the 
affected patient  that shows the p.Arg33Trp  mutation.  
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The second ANG mutation detected in this cohort (c.169C>T, p.Arg33Trp, 
p.Arg57Trp*) affects the nuclear translocation signal of the angiogenin (Figure 9). 
The mutation (p.Arg33Trp) is not reported in the ALSoD database and the only 
information about this variant was that according to the ExAc database it has been 
found in one individual (out of 121.410 individuals).  
*Amino acid numbering according to Human Genome Variation Society guidelines (http://www.hgvs.org/). 
#Amino acid numbering according to the ALS Online Database (http://alsod.iop.kcl.ac.uk/), which has been used in 
the previous published reports on ANG mutations. 
 
 
3.4 C9orf72 gene 
 
Analysis of the C9orf72 gene identified GGGGCC RE in one (Figure 10) out of 66 
ALS patients. The average repeat number based on fragment-length analysis was 5 
(range 2–17 repeats) in the remaining 65 patients, none of whom carried repeat 
expansion. The patient with the repeat expansion also carried the rs3849942 risk 
allele, which was previously described as a part of the Finnish “risk” haplotype 
(Laaksovirta et al., 2010). 
 
 
 
 
Figure 10. PCR products of repeat-primed PCR reactions separated on 310 ABI 
Prism Genetic Analyzer and visualized by GeneMapper software. The difference 
between the wild type and  the shutter amplification of the sample carrying repeat 
expansion is shown.   
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3.4.1 Clinical symptoms of the patient with the C9orf72 RE 
 
This latter patient presented to the neurological unit at age 68 with gradually 
increasing foot drop on the left side due to peroneal weakness. Neurological 
examination revealed mild dysarthria, dysphagia, atrophy, fasciculations and 
fibrillations in the muscles of the tongue. She reported 15 kg weight loss in the 
previous six months and generalized fatigue. She had moderate paraparesis (4/5) with 
diminished deep tendon reflexes and muscle atrophy with fasciculations all over the 
muscles of the lower extremities together with complete left peroneal palsy. The 
signs of lower motor neuron lesion (muscle atrophy, fasciculations) were 
accompanied with brisk deep tendon reflexes in the upper extremities as the only sign 
of upper motor neuron lesion. The ALSFRS-R was 44/48. She was treated with 
duloxetine (60 mg/day) and alprazolam (0.5 mg/day) for depression as well as 
perindopril (3.34 mg/day) for hypertension. Three years before admission, an 
adenoma of one of the parathyroid glands causing hyperparathyroidism was 
surgically removed. On admission, the levels of serum calcium, phosphate and 
parathyroid hormone were within normal ranges. The level of creatine phosphokinase 
was minimally raised (193, normal<170 U/l). There were no other abnormal 
laboratory values observed. Several palpable clumps in the subcutaneous tissue were 
observed all over the body. Histological examination of one such excised clump 
proved to be lipoma. Because of the presence of multiple lipomas, lipomatosis was 
diagnosed; however, mutational analysis of the HMGIC gene (Schoenmakers et al., 
1995) has not been performed. Other entities which can cause multiple lipomas have 
also been considered but not proved. A lumbar IV-V disc protrusion was present, but 
it did not explain the neurological signs and symptoms. The motor and sensory nerve 
conduction velocities were all normal. EMG identified fasciculations, fibrillations, 
positive sharp waves, polyphasic high amplitude (maximum 5 mV) motor units 
without full interference pattern in full effort in several examined muscles of all four 
extremities. There were no sensory abnormalities and no involvement of the external 
eye muscles and sphincter functions. Malignant tumor was excluded by several 
examinations. MRI of the central nervous system did not confirm the presence of 
other diseases. There were no paraproteins or elevated anti-ganglioside IgG or IgM 
found in the serum. Parathyroid dysfunction could not be proved; however, it is noted 
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that debate whether hyperparathyroidism can mimic ALS has been ongoing for the 
last 50 years (Jackson et al., 1998). 
The next generation sequencing approach did not detect mutations in the investigated 
coding regions of the  C9orf72 gene. 
 
3.5 SETX gene 
 
A novel heterozygous missense mutation (c.791A>G, p.Asn264Ser) of 
the SETX gene (Figure 11a) was identified in a Hungarian female patient. The novel 
c.791A>G, p.Asn264Ser SETX mutation identified in this study was confirmed with 
direct sequencing (Figure 11b). SIFT, Polyphen and Mutation Taster analyses 
determined this variant as a damaging, disease-causing mutation. The mutation was 
absent in the patient’s clinically healthy 45-year-old son and in the age- and gender-
matched healthy control individuals. The heterozygous p.Asn264Ser mutation affects 
the N-terminal region of the SETX protein (Figure 12a) and is located in a region 
which is conserved among mammals (Figure 12b). According to the results of the 
Human Splicing Finder online prediction tool, the c.791A>G mutation could result in 
activation of an exonic cryptic donor site, creation of an exonic silencer site (ESS) or 
alteration of an exonic enhancer site (ESE). 
 
 
 
 
Figure 11. A novel mutation in the SETX gene. (a) Next generation sequencing identified the 
novel heterozygous missense SETX mutation. (b) The presence of the mutation was confirmed 
using direct sequencing. (Tripolszki et al., 2017b). 
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3.5.1 Clinical characterictics of the patient with the novel 
p.Asn264Ser SETX mutation 
 
This patient presented with a lower motor neuron disease phenotype, which started 
with an unsteady gait at the age of 65. Electroneurography revealed motor axonal 
loss in the right tibial and peroneal nerves with spared sensory innervation. The 
electromyography indicated subacute and chronic signs of denervation and 
reinnervation. One year later, follow up examinations indicated that denervation had 
spread to several muscles of both lower extremities, and the clinical and 
electrophysiological signs of denervation appeared in the muscles of the upper 
extremities. At the time blood was obtained, the interosseous muscles were wasted, 
dysarthria and dysphagia had developed with diminished gag reflex and lack of deep 
tendon reflexes were observed all over the body. Muscle strength was generally 3/5 
Figure 12. (a) The mutation is located within the N-terminal domain of the encoded protein. (b) 
The region of the mutation is highly conserved in mammals (Tripolszki et al., 2017b) 
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in the upper extremities and 2/5 in the lower extremities. Sensory deficit was not 
observed and the extraocular muscles were not involved in the disease process. The 
external sphincter muscles were also spared. During the 3.5 year course of the 
disease, corticospinal or corticobulbar signs were not detected with physical 
examination and with magnetic resonance images of the central nervous system. 
Progressive weakness was observed. Other diseases causing similar symptoms were 
all excluded (thyroid and parathyroid diseases, paraneoplastic syndromes, 
gammopathies, multifocal motor neuropathy with ganglioside antibodies). Ataxia and 
oculomotor apraxia were not noted in the follow up examinations. The cerebrospinal 
fluid proved to be normal. The patient passed away at the age of 69 and the cause of 
death was determined to be respiratory failure due to weakness of the respiratory 
muscles. No other members of the family were affected. The autopsy revealed a 
decreased number of motor neurons in the spinal cord and diminished number of 
axons in the ventral roots. Hyalineinclusions were noted in the remaining spinal 
motor neurons. Histological examination of the striated muscles (proximal and distal 
in the extremities, in the diaphragm and in the tongue) revealed signs of neurogenic 
atrophy. There were no signs of degeneration in the corticospinal tracts. The motor 
cortex remained intact, and other parts of the brain (temporal and parietal lobes, 
hippocampus, cerebellum, thalamus, pons and the medulla) seemed to be normal 
except some cell loss in the nuclei of the hypoglossal and facial nerve. Together with 
the clinical symptoms, the disease course and the autopsy findings confirmed the 
diagnosis of an atypical ALS form with lower motor neuron involvement. 
 
  
30 
 
4 DISCUSSION 
 
 
In this study, I analyzed SOD1, TARDBP, ANG, C9orf72, SETX and FUS genes in a 
cohort of 66 Hungarian ALS patients, including one single case with a reported 
familial history for the disease (Table 2).  
 
 
 
 
 
Gene 
Age of 
onset/gender Mutation 
Disease 
signs 
Disease 
duration, 
years Other diseases 
ALS 
family 
history Reference 
SOD1 63/Female p.Asp90Ala LMN, UMN, 
B 
12  Lumbar disc protrusions No Andersen 
et al. 1995 
SOD1 67/Female p.Lys91ArgfsTer8 LMN, UMN, 
B, PB 
1  Breast cancer, 
hypertension, 
hypercholesterolemia, 
spondylosis and lumbar 
disc protrusions 
No This study 
SOD1 29/Female p.Leu144Phe LMN, UMN 4  None reported Yes Deng et al. 
1993 
SOD1 46/Female p.Leu144Phe LMN, UMN, 
B 
3  Lumbar disc protrusions No Deng et al. 
1993 
SOD1, 
ANG 
62/Female p.Val14Met, 
p.Met-24Ile 
LMN, UMN 1  Lumbar disc 
protrusions, 
atherosclerosis 
No Deng et al. 
1995 
ANG 54/Male p.Arg33Trp UMN, LMN 3 Spondylarthrosis and 
disc protrusions 
No This study 
TARDBP 62/Male p.Met311Val UMN, LMN, 
B, PB 
3 Lumbar spondylosis No Lemmens 
et al. 2009 
C9orf72 65/Female Repeat Expansion LMN, 
UMN 
0,5  Hyperparathyroidism, 
multiple lipomas, 
hypertension, 
osteoporosis 
No Renton et 
al., 2011; 
DeJesus et 
al.,2011 
SETX 66/Female p.Asn264Ser LMN, B 3 Hypercholesterolaemia, 
spondylarthrosis, 
discopathia lumbalis, 
small white matter 
infarct in the cerebrum 
No This study 
Table 2. Clinical data of Hungarian ALS patients carrying pathogenic variants in SOD1, ANG, 
TARDBP, C9orf72 and SETX genes 
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4.1 Mutations in the SOD1 gene 
 
I identified a novel and likely disease-causing heterozygous frameshift mutation 
(p.Lys91ArgfsTer8) in the SOD1 gene (Figure 2). Three other heterozygous recurrent 
SOD1 missense mutations (p.Val14Met, p.Asp90Ala and p.Leu144Phe) were also 
detected (Figure 13). SOD1 mutations were detected in 7.5% (5/66) of this cohort, in 
line with literature data reporting that SOD1 mutations account for approximately 0–
7% patients with sporadic disease (Andersen, 2006). 
 
The identified novel p.Lys91ArgfsTer8 SOD1 mutation is associated with a typical 
ALS phenotype characterized by lower and upper motor neuron signs; in addition, 
the patient had also suffered from breast cancer, hypertension, hypercholesterolemia, 
spondylosis and lumbar disc protrusions before ALS developed. The disease had a 
late onset at the age of 67 years and progressive course leading to the death of the 
patient within one year after the onset of the signs and symptoms of the disease. The 
two-base-pair deletion of the p.Lys91ArgfsTer8 SOD1 mutation leads to a frameshift 
with the formation of a premature stop codon after the insertion of eight novel amino 
acids, causing a severe truncation of the protein (Figure 2). This truncation abolishes 
the integrity of the intrachain C57–C146 disulfide bridge. Although most mutations 
in the SOD1 gene are missense ones, a few deletions and insertions have been 
described previously causing truncations of different sizes and in most cases 
affecting also the C57-C146 disulfide bridge (http://alsod.iop.kcl.ac.uk/; Abel et al., 
2012). The most comprehensively studied truncation mutant is the Gly127insTGGG 
(G127X), carriers of which developed signs of motor neuron degeneration with a 
rapid disease course (Jonsson et al., 2004). These observations correlate well with the 
clinical manifestations and course of ALS in the investigated Hungarian patient with 
the truncating p.Lys91ArgfsTer8 SOD1 mutation. SOD1 protein with truncating 
mutations exhibits structural instability causing misfolding in the mutated enzyme 
(Jonsson et al., 2004) which can consequently aggregate in motor neurons and lead to 
the development of ALS (Forsberg et al., 2011). 
 
With the exception of the p.Asp90Ala SOD1 mutation, the detected recurrent 
mutations are all associated with typical ALS phenotypes, characterized by lower and 
upper motor neuron signs, late onset and progressive disease course. In the case of 
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the patient with the p.Asp90Ala heterozygous mutation, lower limb involvement and 
relatively long duration of the disease course was detected similarly to cases reported 
previously (Robberecht et al., 1996; Andersen et al., 2006). The p.Asp90Ala 
mutation is the most common SOD1 mutation in Europe (Andersen 2001), and it can 
be inherited in either a dominant or recessive manner (Robberecht et al., 1996).  
 
The p.Leu144Phe missense mutation, which is the most prevalent mutation in the 
Balkan region (ALSoD), was detected in a familial and in a sporadic case. The 
clinical symptoms and the course of the disease were similar in these two patients. To 
note, the patient with a positive family history developed ALS symptoms at a 
relatively early age, whereas onset for the other patient was late. Although a 
significant number of patients with this mutation have lower limb onset (Corcia et 
al., 2011), both of the patients reported in this study developed upper and lower 
motor neuron signs. The rare p.Val14Met mutation was detected in an apparently 
sporadic case in a female patient with upper and lower motor neuron signs. None of 
the SOD1 mutations detected in these ALS patients was identified in 110 healthy 
Hungarian controls.  
 
 
 
 Figure 13. Diagram of SOD1 mutations detected in Hungarian patients. The amino acid 
sequence is shown, with the location of introns.  
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4.2 Mutations in the TARDBP gene 
 
A known disease-causing mutation (p.Met311Val) has been detected in the last exon 
of the TARDBP gene. With the exeption of one mutation (p.Asp169Gly in exon 4), 
all the identified mutations are localized across the entire C-terminal sequence of 
TDP-43 with a tendency of clustering in specific positions. The p.Met311Val 
mutation is located in the C-terminal part of the protein, the glycine-rich region that 
may mediate interactions with other proteins, including heterogenous 
ribonucleoproteins (Buratti et al., 2005). This affected methionine is evolutionary 
well conserved from Homo sapiens to Xenopus tropicalis.  
 
4.3 Mutations in the ANG gene 
 
Two heterozygous mutations were detected in the ANG gene (c.3G>A, p.Met-24Ile, 
p.Met1Ile*; c.169C>T, p.Arg33Trp, p.Arg57Trp*).  
The p.Met-24Ile mutation, located in the signal peptide region of the protein, was 
first described by Conforti et al. (2008). This mutation was detected in the same 
Hungarian patient who carried the SOD1 p.Val14Met mutation. The biological 
function of the signal peptide is not entirely understood, hence it is difficult to predict 
the effect of the p.Met-24Ile mutation. Nonetheless, the Met-24I mutation affects the 
start codon (ATG) of the gene, which may influence the correct translation of the 
protein. The co-occurrence of different variants in ALS associated genes is also 
detected in other ALS cohort screenings (Kenna et al., 2013; Cady et al., 2015; 
Cirulli et al., 2015; Krüger et al., 2016). As it was previously mentioned in the text, 
this patient with the SOD1 p.Val14Met mutation showed a very progressive disease 
course that could be explained by the fact that she carried disease-causing mutations 
in two ALS associated genes. Cady et al. (2015) described that 3,8% of the 
investigated patients carried pathogenic mutations in more than one gene and those 
patients had disease onset 10 years earlier, which supports a model of ALS where the 
additive or synergistic effects of multiple defective genes influence disease 
phenotype. On the contrary, Cirulli et al. (2015) did not report an influence of the 
number of variants on the disease phenotype. Due to the small sample size, I could 
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not make statistically significant observations on a possible correlation between the 
number of pathogenic variants and disease phenotype. 
The p.Arg33Trp (p.Arg57Trp*) affects the nuclear translocation signal of the 
angiogenin. Amino acids 29IMRRRGL35 represent the nuclear localization signal and 
helps in nuclear translocation of angiogenin. The arginine residues 31RRR33 are 
critical in governing the nuclear translocation activity of angiogenin. The R33 is 
essential to nuclear translocation and residues 31RR32 modulate this process. 
Moroinau et al. (1994) described that R33A mutant is not translocated to the nucleus 
and lacks of angiogenic activity (Moroianu and Riordan, 1994). P.Arg33Trp is not 
reported in the ALSoD database and to my knowledge, there is no report about tis 
variant in the literature. The only previous information about this variant is that it has 
been found in one out of 121.410 individuals in the Exome Aggregation Consortium. 
 
4.4 Repeat expansion of the C9orf72 gene 
 
C9orf72 repeat expansion was detected only in one patient of 66. The patient 
carrying the RE variant also carried the previously described rs3849942 risk allele 
(Laaksovirta et al., 2010; DeJesus-Hernandez et al., 2011) in heterozygous form. 
According to earlier findings, the “A” allele of SNP rs3849942 was significantly 
associated to the expanded C9orf72 allele (DeJesus-Hernandez et al., 2011). The 
presence of the risk allele suggests that the common founder is also shared by the 
investigated Hungarian patient with the C9orf72 repeat expansion. I screened 110 
controls of Hungarian origin to establish the allele frequencies in this genomic 
position. The allele frequency of the minor allele in the Hungarian population (MAF 
(A) = 0.18) correlates well with the data from 1000 Genomes Database 
(www.1000genomes.org/). I observed that the average repeat number was 5 (range: 
2–17 repeats) in the remaining 65 patients who did not carry repeat expansions.  
In this study, I identified the hexanucleotide RE of the C9orf72 gene only in one 
sporadic patient. These results suggest that the frequency of RE observed in the 
Hungarian ALS patients (1,5%) is significantly lower than in Western European 
populations  (Majounie et al., 2012; Ratti et al., 2012; Fogh et al., 2014), further 
demonstrating that the frequency of genetic factors for ALS varies among different 
geographic regions.  
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I did not identify any mutations in the coding regions of the C9orf72 gene. These 
results correlate well with the data reported in the literature. Recently, Liu et al. 
(2016) reported a splice site mutation in one patient with ALS, which is the second 
disease-causing variant reported in the C9orf72 gene. In addition, there are different 
studies that failed to detect any disease-causing mutations in the coding regions of 
the C9orf72 gene (Koppers et al., 2013; Kenna et al., 2013).  
 
4.5 Mutations of the SETX gene 
 
A novel, disease-causing heterozygous missense mutation has been identified 
(p.N264S) in the SETX gene. To date, only 17 pathogenic SETX mutations (Table 4) 
have been implicated in the development of the autosomal dominant juvenile form, 
ALS4. The typical phenotype, present in the majority of the ALS4 patients, presents 
as a combination of lower and upper motor neuron impairments (Avemaria et al., 
2011; Hirano et al., 2011; Saracchi et al., 2014). 
The identified novel p.Asn264Ser SETX mutation is associated with an unusual ALS 
phenotype characterized by lower motor neuron impairment only. These results 
further support the accepted view that ALS and lower MNDs are not different disease 
entities, but that, instead, they are clinical variants of the same disease spectrum. The 
phenotypic variation can be explained by yet unidentified genetic modifiers, 
environmental and/or life style factors. The unusual phenotype observed in the 
reported Hungarian patient is not unique in the literature of pathogenic 
heterozygous SETX mutations. A similar atypical phenotype has been described in a 
Chinese patient carrying the p.T1118I heterozygous missense mutation of 
the SETX gene (Zhao et al., 2009). Although the p.N264S mutation is located within 
the N-terminal region of the protein and the p.T1118I mutation is located in a region 
of yet unknown function, both of these mutations result in the development of the 
same unusual ALS4 phenotype. Further studies are needed to elucidate the 
underlying mechanism responsible for the observed unusual phenotypes associated 
with the heterozygous p.N264S and p.T1118I missense mutations of the SETX gene 
(Table 3). 
The 17 known heterozygous missense mutations of the SETX gene are located in 
exons 1, 5, 8, 11, 12, 13, 17 and 24 (Table 4). 
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SETX 
Mutation 
Amino Acid 
Substitution 
Ethnic 
Origin 
Age of 
Onset 
Lower Motor 
Neuron Sign 
Upper Motor 
Neuron Sign 
Bulbar Sign 
Sensory 
Impairment 
Reference 
c.791A>G p.N264S Hungarian 65 + - + - This study 
c.3353C>T p.T1118I 
Chinese 
(Han) 
42 + - + - 
Zhao et al., 
2009 
 
 
Four of the 17 mutations are located within the helicase domain of the SETX protein 
(Chen et al., 2004; Hirano et al., 2011; Kenna et al., 2013; Saracchi et al., 2014). In 
AOA2, homozygous or compound heterozygous missense mutations located within 
the helicase domain are generally associated with less severe phenotypes than the 
mutations affecting other regions of the protein (Moreira et al., 2004; Anheim et al., 
2009). A similar genotype–phenotype association has not been observed for the 
heterozygous missense mutations associated with ALS4. However, in ALS4, 
mutations impairing the region of the helicase domain are associated with cortical 
and spinal motor neuron impairment, whereas others located outside of this region 
can lead to the development of either spinal or bulbar motor neuron involvement 
(Table 4). 
It has also been demonstrated that, in AOA2, missense mutations affecting the N-
terminal or the helicase domain of SETX cause phenotypes similar to those caused 
by deletions, nonsense or frameshift mutations (Chen et al., 2006). However, only 
missense SETX mutations have been implicated in the development of ALS4 to date 
(Avemaria et al., 2011; Hirano et al., 2011; Kenna et al., 2013; Saracchi et al., 2014); 
deletions, nonsense, frameshift or other types of mutations have not yet been detected 
for this disease (Table 4). 
 
 
 
 
 
Table 3. Clinical features of the atypical ALS4 phenotype. 
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This study further widens the geographic range for the origin of disease-causing 
heterozygous missense mutations of the SETX gene, which have already been 
implicated in ALS in patients from different countries (Avemaria et al., 2011; Hirano 
et al., 2011; Kenna et al., 2013; Saracchi et al., 2014). To my knowledge, my study 
is the first demonstrating a novel SETX mutation in the Hungarian ALS population 
(Table 4). 
  
SETX 
Mutation 
Amino Acid 
Substitution 
Affected 
Exon 
Impaired 
Region of the 
Protein 
Age of 
Onset 
Affected 
sites 
Reference 
c.8C>T p.T3I 1 N-terminal Domain 8 Spinal Chen et al., 2004 
c.791A>G p.N264S 5 N-terminal Domain 65 Both This study 
c.814C>G p.H272D 5 N-terminal Domain 66 Bulbar Kenna et al., 2013 
c.1166T>C p.L389S 8 N-terminal Domain 
17 Spinal Chen et al., 2004, 
24 Spinal 
Avemaria et al., 
2011 
c.2755G>C p.V919L 8 Unknown Function 68 Both Kenna et al., 2013 
rc.2842C>A p.P948T 8 Unknown Function 58 Bulbar Kenna et al., 2013 
c.2975A>G p.K992R 8 Unknown Function 78 Bulbar Kenna et al., 2013 
c.3353C>T p.T1118I 8 Unknown Function 42 Both Zhao et al., 2009 
c.4660T>G p.C1554G 8 Unknown Function 6 Spinal Hirano et al., 2011 
c.5587A>G p.T1863A 11 Unknown Function 61 Other Kenna et al., 2013 
c.5842A>G p.M1948V 12 Helicase Domain 47 Spinal Kenna et al., 2013 
c.6052A>G p.K2018E 13 Helicase Domain 
54 
Spinal 
Saracchi et al., 
2014 
c.6085C>G p.K2029E 13 Helicase Domain 35 Spinal Hirano et al., 2011 
c.6407G>A p.R2136H 17 Helicase Domain 6 Spinal Chen et al., 2004 
c.7640T>C p.I2547T 24 Unknown Function 30 Spinal Hirano et al., 2011 
c.7645G>A p.V2549I 24 Unknown Function 64 Spinal Kenna et al., 2013 
c.7682C>T p.S2561L 24 Unknown Function 84 Spinal Kenna et al., 2013 
Table 4. Clinical manifestations of SETX mutations in ALS4 (Tripolszki et al., 2017b) 
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4.6 Mutations in the FUS gene 
 
No mutations in FUS, were detected in the Hungarian patients. FUS mutations have 
been detected in two regions of the gene that consequently affect the encoded 
protein: approximately one-third are located within exon 3 and 6 and impair the 
glutamine-glycine-serine-tyrosine-rich and the arginine-glycine-glycine-rich domains 
of the protein. Two-thirds of the mutations are located within the region including 
exons 12 to 15, which encodes a zinc-finger and arginine-glycine-glycine-rich 
domains (Shang and Huang, 2016). Based on my results, I hypothesize 
that FUS mutations in the Hungarian ALS population might be very rare. This 
hypothesis is supported by the literature, as FUS mutations have been reported to 
contribute to the development of the disease in approximately 0.5% of the patients 
(Kenna et al., 2013). 
 
Based on my results and the results of previous studies, I also emphasize that the 
genetic screening of the Mendelian ALS-associated genes might not elucidate the 
causative genetic variant in the majority of ALS cases (Kenna et al., 2013; Cirulli et 
al., 2015). The genetic heterogeneity of ALS is extremely complex: rare mutations of 
Mendelian genes and common variants of non-Mendelian genes can also contribute 
to the development of the disease (Abel et al., 2012). This comprehensive study adds 
novel data to the genetic and phenotypic diversity of ALS and indicates that complex 
approaches, high-throughput methods and large-scale studies are needed to 
understand the genetic heterogeneity of this disease. 
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5 SUMMARY 
 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by 
the degeneration of the motor neurons. Approximately 90% of ALS cases are 
sporadic the remaining 10% are familial. Due to the complex genetic background of 
the disease, the underlying disease-causing variant is rarely established for individual 
cases. More than 20 major ALS genes are implicated in the Mendelian ALS forms 
and about 100 genes are associated with increased susceptibility for the development 
of the disease.  
The aim of this study was to investigate Mendelian-disease causing genes in a group 
of Hungarian ALS patients (n=66). Considering the onset, the symptoms and the 
course of the disease, six genes (superoxide dismutase, SOD1; TAR DNA binding 
protein, TARDBP; angiogenin, ANG;  senataxin, SETX; fused in sarcoma, FUS and 
chromosome 9 open reading frame 72, C9orf72) were selected for mutation 
screening.  
The patients (n=66) participating in this study were recruited from the Department of 
Neurology, University of Szeged, Hungary. All patients and age- and sex-matched 
healthy controls (n=110) were of Hungarian ancestry. Genomic DNA was isolated 
from blood. SOD1, TARDBP and ANG genes were analysed by Sanger sequencing. 
The GGGGCC hexanucleotide repeat in C9orf72 was analyzed by a two-step 
protocol, including a first step of polymerase chain reaction amplification using 
genotyping primers. The fragment length analysis was performed using GeneScan. 
Only samples presenting with a single peak/amplification product were further 
analyzed in the second step by repeat-primed polymerase chain reaction. Targeted 
high-throughput sequencing was used for the analysis of the coding regions of the 
SETX, FUS and C9orf72 genes. 
Direct sequencing revealed a novel heterozygous frameshift mutation 
(c.275_276delAA, p.Lys92ArgfsX8) and three recurrent missense mutations 
(p.Val14Met; p.Asp90Ala and p.Leu144Phe in two patients) in the SOD1 gene in 
five patients. The novel heterozygous SOD1 mutation (p.Lys91ArgfsTer8) is located 
in the fourth exon of the gene and led to a frameshift with the insertion of 8 novel 
amino acids and the formation of premature stop codon at the new amino acid 
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position 99. A known missense mutation (p.Met311Val) was detected in the 
TARDBP gene, which is located in the C-terminal part of the protein, the glycine-rich 
region that may mediate interactions with other proteins. Two heterozygous 
mutations were identified in the ANG gene (c.3G>A, p.Met-24Ile; c.169C>T, 
p.Arg33Trp). The p.Met-24Ile mutation was detected in the same Hungarian patient 
who carried the SOD1 p.Val14Met mutation, and is located in the signal peptide 
region of the protein. The second ANG mutation (c.169C>T, p.Arg33Trp) affects the 
nuclear translocation signal of the angiogenin. C9orf72 repeat expansion was 
detected in one sporadic female patient. She also carried the previously described 
rs3849942 risk allele in heterozygous form. Targeted high-troughput sequencing 
revealed a novel heterozygous missense mutation (c.791A>G, p.Asn264Ser) in the 
SETX gene. The mutation affects the N-terminal region of the SETX protein and is 
located in a region which is evolutionary conserved among mammals.  
In conclusion, I performed the first genetic analysis of SOD1, TARDBP, ANG, 
C9orf72, SETX and FUS genes in a cohort of Hungarian ALS patients. My study 
further widens the geographic range for the origin of disease-causing heterozygous 
missense and frameshift mutations of the SOD1, TARDBP, ANG, C9orf72 and SETX 
genes, which have already been implicated in ALS patients from different countries 
of origin.  
  
41 
 
6 ACKNOWLEDGEMENTS 
 
I would like to thank to Dr. Nikoletta Nagy for her great supervising activity.  
I would like to thank to Prof. Dr. Márta Széll for the opportunity to perform the 
genetic investigations of this study in the molecular laboratory of the Department of 
Medical Genetics, University of Szeged.  
I am grateful to Dr. József I Engelhardt, Dr. Péter Klivényi, Nóra Török and Dr. 
László Vécsei for the neurological examinations and for enrolling the pateints into 
the study. 
Special thanks to Dr. Antonia Ratti, Dr. Cinzia Tiloca and Dr. Vincenzo Silani 
(Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto 
Auxologico Italiano, Milan, Italy) for providing the C9orf72 repeat expansion 
positive samples.  
I am extremely grateful to Dr. Bernadett Csányi for her help in the C9orf72 
repeat expansion analysis. I would like to thank to Dr. Éva Kereszty for the 
opportunity to perform the C9orf72 repeat expansion analysis in the laboratory of the 
Department of Forensic Medicine, University of Szeged. 
I would like to express my gratitude to Dr. Vincent Procaccio and Dr. David 
Goudenege (University of Angers, France) for their guidance and help in the 
bioinformatic analysis of the next generation sequencing data. 
Special thanks to all my colleagues for their kind help at the Department of 
Medical Genetics, University of Szeged. 
  
42 
 
7 ELECTRONIC DATABASE INFORMATION 
 
 Ensemble Genome Browser 
http://www.ensembl.org/Homo_sapiens/Info/Index  
 Online Mendelian Inheritance in Man  https://www.omim.org  
 UCSC Genome Browser, Primer3  https://genome.ucsc.edu  
 ALS Online Genetics Database http://alsod.iop.kcl.ac.uk/  
 1000 Genomes Database (www.1000genomes.org/)  
 dbSNP http://www.ncbi.nlm.nih.gov/project/SNP  
 Exome Aggregation Consortium (ExAC) database 
http://exac.broadinstitute.org 
 SIFT http://sift.bii.a-star.edu.sg/ 
 Polyphen-2 http://genetics.bwh.harvard.edu/pph2 
 Mutation Taster http://mutationtaster.org  
 Swiss-Model protein structure homology-modeling server 
http://swissmodel.expasy.org/ 
 Human Splicing Finder http://www.umd.be/HSF3/  
 
 
 
 
 
 
 
 
 
43 
 
LIST OF ABBREVIATIONS 
ALS Amyotrophic lateral sclerosis 
ALSFRS-R ALS Functional Rating Scale R 
ANG Angiogenin 
AOA2 Ataxia with oculomotor apraxia type 2 
C9orf72 Chromosome 9 open reading frame 72 
EMG Electrimyography 
ENG Electroneurography 
FUS Fused in sarcoma 
LMN Lower motor neuron 
MND Motor neuron disease 
MRI Magnetic Resonance Imaging 
NGS Next-generation sequencing 
PCR Polimerase chain reaction 
PLS Primary lateral sclerosis 
PMA Progressive muscular atrophy 
RE Repeat expansion 
SETX Senataxin 
SNP Single nucleotide polymorphism 
SOD1 Superoxide dismutase 1 
TARDBP Transactive response DNA binding 
protein 
UMN Upper motor neuron 
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9 APPENDIX
  
 
